The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

Recruiting Phase 4 Interventional Study
Aging
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
21 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Basic Science
Participants needed
60 (estimated)
Sponsor
State University of New York at Buffalo · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study focuses on the role of neutrophils in shaping the adaptive immune response to the anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Both sexes * Have not been vaccinated with any licensed or experimental pneumococcal vaccine * Ages 21-40; and ≥65. Individuals \>60 years old will also be recruited in case we find no unvaccinated people ≥65 years old * Free of acute infections within the last 2 weeks * Did n…
Contacts

Elsa Bou Ghanem, PhD

7168292422

elsaboug@buffalo.edu

CONTACT